Germany gives thumbs up to Viiv's Triumeq for HIV
This article was originally published in Scrip
Executive Summary
Germany's early benefit assessment authority IQWiG has given a largely positive evaluation of Viiv Healthcare's HIV regimen Triumeq (dolutegravir/abacavir/lamivudine). The institute said that the product showed considerable added benefit over comparators in previously untreated adult patients.